Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Agenus Inc.
After the presentation of stellar long-term survival data at ESMO for Kisqali in women with HR+/HER2- advanced breast cancer, Novartis is planning to knock Pfizer's Ibrance off its CDK4/6 inhibitor perch with the help of a head-to-head trial.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
After more than a decade of sky-high rates of on-time regulatory action by the US FDA, missed user fee goal dates are back in a pretty big way – and it’s not just JAK inhibitor and COVID-19 delays.
Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.
- Contract Research, Toxicology Testing-CRO
- Drug Discovery Tools
- Other Names / Subsidiaries
- Antigenics Inc. Aronex Pharmaceuticals AgenTus Therapeutics, Inc. Agenus Royalty Fund, LLC Agenus Switzerland Inc. Agenus UK Limited 4-Antibody